Cargando…
A Survey of Therapeutic Drug Monitoring Status in China
To understand the status of therapeutic drug monitoring (TDM) in China Mainland, and thus lay down the foundation for further improvement in TDM. METHODS: In the present study, a nationwide questionnaire survey was conducted, which was distributed and collected using a mobile‐based application. Clin...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Therapeutic Drug Monitoring
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013164/ https://www.ncbi.nlm.nih.gov/pubmed/36920501 http://dx.doi.org/10.1097/FTD.0000000000001060 |
_version_ | 1784906762753671168 |
---|---|
author | Yin, Tao. Liang, Hongyan Huang, Qi Zhou, Boting Tang, Mimi Lou, Jiang Xiang, Dong |
author_facet | Yin, Tao. Liang, Hongyan Huang, Qi Zhou, Boting Tang, Mimi Lou, Jiang Xiang, Dong |
author_sort | Yin, Tao. |
collection | PubMed |
description | To understand the status of therapeutic drug monitoring (TDM) in China Mainland, and thus lay down the foundation for further improvement in TDM. METHODS: In the present study, a nationwide questionnaire survey was conducted, which was distributed and collected using a mobile‐based application. Clinicians, pharmacists, and clinical laboratory physicians belonging to different levels of public hospitals were involved as subjects/objects. The contents of the survey included TDM implementation in their hospital and information regarding their opinions and suggestions on TDM work. Mann–Whitney test was used to compare the difference between top tertiary hospitals and non–top tertiary hospitals. RESULTS: A total of 475 questionnaires were collected, 383 from top tertiary hospitals (3A hospitals) and 92 from non–top tertiary hospitals (other than 3A hospitals). A total of 240 clinicians, TDM pharmacists, and clinical laboratory physicians were involved, with an effective rate of 50.5%. Top tertiary hospitals were associated with certain advantages, such as the number of TDM testing facilities, annual sample size, number of monitoring varieties, and interpretation rate of monitoring reports, compared with non–top tertiary hospitals. In particular, β-lactamase inhibitor, olanzapine, carbamazepine, and glucocorticoids seemed to be the main projects that clinicians wanted to assess. The drugs for which TDM was commonly performed included vancomycin, valproic acid, carbamazepine, phenytoin sodium, and methotrexate. The most commonly used detection methods include high-performance liquid chromatography, immunization, 2D-LC, and LC-MS. The monitoring concentration range was found to be inconsistent for most of the drugs. Currently, no unified regulation exists for TDM charges in China, which is no more than ¥200 in general. Clinicians rely on pharmacists for professional guidance. Importantly, improvement in the interpretation of monitoring reports, proficiency testing, and cooperation with clinical departments may aid in improving the level of TDM service. CONCLUSIONS: This survey objectively reflected the current status of TDM work in hospitals in China, and provided a strong reference base for devising strategies for improvement and effective execution of TDM work. |
format | Online Article Text |
id | pubmed-10013164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Therapeutic Drug Monitoring |
record_format | MEDLINE/PubMed |
spelling | pubmed-100131642023-03-15 A Survey of Therapeutic Drug Monitoring Status in China Yin, Tao. Liang, Hongyan Huang, Qi Zhou, Boting Tang, Mimi Lou, Jiang Xiang, Dong Ther Drug Monit Review Article To understand the status of therapeutic drug monitoring (TDM) in China Mainland, and thus lay down the foundation for further improvement in TDM. METHODS: In the present study, a nationwide questionnaire survey was conducted, which was distributed and collected using a mobile‐based application. Clinicians, pharmacists, and clinical laboratory physicians belonging to different levels of public hospitals were involved as subjects/objects. The contents of the survey included TDM implementation in their hospital and information regarding their opinions and suggestions on TDM work. Mann–Whitney test was used to compare the difference between top tertiary hospitals and non–top tertiary hospitals. RESULTS: A total of 475 questionnaires were collected, 383 from top tertiary hospitals (3A hospitals) and 92 from non–top tertiary hospitals (other than 3A hospitals). A total of 240 clinicians, TDM pharmacists, and clinical laboratory physicians were involved, with an effective rate of 50.5%. Top tertiary hospitals were associated with certain advantages, such as the number of TDM testing facilities, annual sample size, number of monitoring varieties, and interpretation rate of monitoring reports, compared with non–top tertiary hospitals. In particular, β-lactamase inhibitor, olanzapine, carbamazepine, and glucocorticoids seemed to be the main projects that clinicians wanted to assess. The drugs for which TDM was commonly performed included vancomycin, valproic acid, carbamazepine, phenytoin sodium, and methotrexate. The most commonly used detection methods include high-performance liquid chromatography, immunization, 2D-LC, and LC-MS. The monitoring concentration range was found to be inconsistent for most of the drugs. Currently, no unified regulation exists for TDM charges in China, which is no more than ¥200 in general. Clinicians rely on pharmacists for professional guidance. Importantly, improvement in the interpretation of monitoring reports, proficiency testing, and cooperation with clinical departments may aid in improving the level of TDM service. CONCLUSIONS: This survey objectively reflected the current status of TDM work in hospitals in China, and provided a strong reference base for devising strategies for improvement and effective execution of TDM work. Therapeutic Drug Monitoring 2023-04 2023-03-01 /pmc/articles/PMC10013164/ /pubmed/36920501 http://dx.doi.org/10.1097/FTD.0000000000001060 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Review Article Yin, Tao. Liang, Hongyan Huang, Qi Zhou, Boting Tang, Mimi Lou, Jiang Xiang, Dong A Survey of Therapeutic Drug Monitoring Status in China |
title | A Survey of Therapeutic Drug Monitoring Status in China |
title_full | A Survey of Therapeutic Drug Monitoring Status in China |
title_fullStr | A Survey of Therapeutic Drug Monitoring Status in China |
title_full_unstemmed | A Survey of Therapeutic Drug Monitoring Status in China |
title_short | A Survey of Therapeutic Drug Monitoring Status in China |
title_sort | survey of therapeutic drug monitoring status in china |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10013164/ https://www.ncbi.nlm.nih.gov/pubmed/36920501 http://dx.doi.org/10.1097/FTD.0000000000001060 |
work_keys_str_mv | AT yintao asurveyoftherapeuticdrugmonitoringstatusinchina AT lianghongyan asurveyoftherapeuticdrugmonitoringstatusinchina AT huangqi asurveyoftherapeuticdrugmonitoringstatusinchina AT zhouboting asurveyoftherapeuticdrugmonitoringstatusinchina AT tangmimi asurveyoftherapeuticdrugmonitoringstatusinchina AT loujiang asurveyoftherapeuticdrugmonitoringstatusinchina AT xiangdong asurveyoftherapeuticdrugmonitoringstatusinchina AT yintao surveyoftherapeuticdrugmonitoringstatusinchina AT lianghongyan surveyoftherapeuticdrugmonitoringstatusinchina AT huangqi surveyoftherapeuticdrugmonitoringstatusinchina AT zhouboting surveyoftherapeuticdrugmonitoringstatusinchina AT tangmimi surveyoftherapeuticdrugmonitoringstatusinchina AT loujiang surveyoftherapeuticdrugmonitoringstatusinchina AT xiangdong surveyoftherapeuticdrugmonitoringstatusinchina |